Clinical Trials List
2015-10-01 - 2020-06-30
Phase III
Recruiting3
Terminated3
ICD-10C67
Malignant neoplasm of bladder
ICD-9188.0
Malignant neoplasm of trigone of urinary bladder
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Yu-Min Yeh Division of Hematology & Oncology
- Shang-Yin Wu Division of Hematology & Oncology
- Wu-Chou Su Division of Hematology & Oncology
- Sin-Syue Li Division of Hematology & Oncology
- Wei-Pang Chung Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Audit
None
Co-Principal Investigator
- Shian-Shiang Wang Division of Urology
- 熊小澐 Division of Urology
- 洪啟峰 Division of Urology
- Cheng-Kuang Yang Division of Urology
- Chuan-Shu Chen Division of Urology
- Cheng-Che Chen Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yeong-Shiau Pu Division of Urology
- Chia-Chi Lin Division of Hematology & Oncology
- - - Division of Urology
- CHUNG-HSIN CHEN Division of Urology
- - - Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Audit
None
Co-Principal Investigator
- Yen-Hwa Chang Division of Urology
- Chueh-Chuan Yen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
6 Terminated
Audit
None
Co-Principal Investigator
- 陳彥豪 Division of Hematology & Oncology
- 陳彥仰 Division of Hematology & Oncology
- 劉建廷 Division of Hematology & Oncology
- Tai-Jan Chiu Division of Hematology & Oncology
- Shau-Hsuan Li Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Rita cheng Division of Hematology & Oncology
- 劉忠一 Division of Hematology & Oncology
- 張英勛 Division of Hematology & Oncology
- Yung-Chia Kao Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
7 Terminated
Audit
CRO
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
40 participants
-
Global
1340 participants